ANI Pharmaceuticals (ANIP) Stock Forecast & Price Target
Score
ANI Pharmaceuticals, Inc. price target
| ANIP | |
|---|---|
| Low | $85.00 |
| Average | $99.50 |
| High | $119.00 |
| Upside vs current price | +39.3% |
The average target of $99.50 is +39.3% versus the current ANIP price of $71.44.
ANI Pharmaceuticals, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 3 |
| Buy | 4 |
| Hold | 2 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
9 analysts cover ANIP.
ANI Pharmaceuticals, Inc. EPS and revenue estimates
Published annual figures for ANIP on this page are 2026 EPS $9.26, 2027 EPS $10.13. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $9.26 | $1.10B |
| 2027 | $10.13 | $1.22B |
Is ANI Pharmaceuticals, Inc. a buy or sell?
Of the 9 analysts covering ANI Pharmaceuticals, Inc., 7 rate it a buy (3 strong buy and 4 buy), 2 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The ANIP consensus label is Buy, beside 7 buy-side ratings and 0 sell-side ratings.
The average target of $99.50 implies +39.3% versus the current price of $71.44.
The ANIP rating block is 9 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the ANI Pharmaceuticals, Inc. forecast
the ANI Pharmaceuticals, Inc. is priced by the street between $85.00 and $119.00, average $99.50.
The gap from the $71.44 price to the ANIP average is +39.3%.
The ANIP rating mix is lopsided rather than split: 7 of 9 analysts are on the buy side, 2 are at hold, and 0 are on the sell side, and the published consensus is Buy.
the ANI Pharmaceuticals, Inc. has a rising EPS path, $9.26 for 2026 and $10.13 for 2027.
With 9 analysts on ANIP, the average is a small sample.
ANI Pharmaceuticals, Inc. forecast questions
What is the ANIP price target?
The published range for ANIP is $85.00 to $119.00, with an average of $99.50. That average is +39.3% versus the current price of $71.44.
Is ANI Pharmaceuticals, Inc. a buy or sell?
Of the 9 analysts covering ANI Pharmaceuticals, Inc., 7 rate it a buy, 2 rate it a hold, and 0 rate it a sell. The consensus is Buy, leaving ANIP at 7 buy ratings, 2 holds, and 0 sells.
What is the EPS estimate for ANI Pharmaceuticals, Inc.?
Analyst EPS estimates for ANI Pharmaceuticals, Inc.: 2026 $9.26, 2027 $10.13.
What is the revenue estimate for ANI Pharmaceuticals, Inc.?
Analyst revenue estimates for ANI Pharmaceuticals, Inc.: 2026 $1.10B, 2027 $1.22B.
How many analysts cover ANIP?
9 analysts cover ANIP. Their consensus on ANIP is Buy, across those 9.